Beam Therapeutics Inc. (BEAM)

22,24 -0,29 (-1,29%) Al cierre: 04:00PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142-1016
United States
857 327 8775
https://beamtx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 436

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. John M. Evans M.B.A.	CEO & Director	1,13M	N/A	1978
Dr. Giuseppe Ciaramella Ph.D.	President	955,55k	5,81M	1969
Ms. Terry-Ann Burrell M.B.A.	CFO & Treasurer	728,2k	3,06M	1977
Ms. Anne Marie Woodland	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. John Lo Ph.D.	Chief Commercial Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Beam Therapeutics Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 5; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.